Enhabit (NYSE:EHAB – Get Rating) and Cancer Treatment (OTCMKTS:CTHZ – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.
This table compares Enhabit and Cancer Treatment’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Enhabit and Cancer Treatment’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Enhabit||$1.11 billion||0.62||$111.10 million||N/A||N/A|
Institutional & Insider Ownership
28.7% of Enhabit shares are owned by institutional investors. 56.1% of Cancer Treatment shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent recommendations for Enhabit and Cancer Treatment, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Enhabit presently has a consensus target price of $17.00, indicating a potential upside of 23.73%. Given Enhabit’s higher possible upside, equities analysts plainly believe Enhabit is more favorable than Cancer Treatment.
Enhabit beats Cancer Treatment on 7 of the 8 factors compared between the two stocks.
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
About Cancer Treatment
Cancer Treatment Holdings, Inc., through its subsidiaries, engages in providing IT-enabled services; the exploitation of an invention related to the on-site production of chlorine gas and related compounds; and providing radiation therapy, diagnostic imaging, and other medical related services. The company, through a 50% interest in a joint venture, offers IT-enabled services, including medical transcriptions, billing and collecting, bookkeeping, and claims processing services. The company enables users to manufacture chlorine on-site and when needed through its device. It has a 51% interest in a radiation therapy center located in Logan, West Virginia. In addition, through its wholly owned subsidiary, CTI Management Corp., the company's president provides management services. The company is based in Carson City, Nevada.
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.